Covering: up to 2019 There is significant demand for new aminoglycoside antibiotics due to the widespread emergence of multidrug-resistant Gram-negative bacteria and their high toxicity, but these are not easily accessible in nature because their biosynthetic gene clusters are less commonly found in actinomycetes than are other natural products. Mining minor aminoglycoside components whose pharmacological activity has not yet been assessed could be an alternative approach for the development of next-generation antibiotics for use in the post-antibiotic era. Here, we review the biosynthetic steps responsible for the structural diversity of aminoglycosides and highlight current developments regarding the use of natural minor and semi-synthetic aminoglycosides as promising therapeutic leads or candidates.
Bibliographical noteFunding Information:
This work was supported by National Research Foundation of Korea (NRF) grants funded by the Ministry of Science and ICT (2019R1A2B5B03069338: Y. J. Y.; 2019R1F1A1055442: J. W. P.) and the Ministry of Education (2019R1I1A1A01062130: Y. H. B), the Collaborative Genome Program of the Korea Institute of Marine Science and Technology Promotion (KIMST) funded by the Ministry of Oceans and Fisheries (20180430: Y. J. Y.), a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare (HI18C1664: Y. J. Y.), and the Cooperative Research Program for Agriculture Science & Technology Development funded by the Rural Development Administration (PJ013179: J. W. P.).
© 2020 The Royal Society of Chemistry.
ASJC Scopus subject areas
- Drug Discovery
- Organic Chemistry